| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 26.05.
| Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In AEterna Zentaris Inc. To Contact The Firm | | 72 | PR Newswire |
| NEW YORK, May 25, 2012 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AEterna Zentaris Inc. ("AEterna" or...
Mehr lesen zu:
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In AEterna Zentaris Inc. To Contact The Firm | |
| 18.05.
| M&A Activity and a Growing Rate of FDA Approvals Contributing Factors to Biotech Industry's Success The Paragon Report Provides Stock Research on AEterna Zentaris and Celsion | | 65 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/18/12 -- The Biotechnology Industry has shown investors some impressive gains this year. The SPDR S&P Biotech ETF (XBI) is up nearly 25 percent year-to-date. A flurry...
Mehr lesen zu:
M&A Activity and a Growing Rate of FDA Approvals Contributing Factors to Biotech Industry's Success The Paragon Report Provides Stock Research on AEterna Zentaris and Celsion | |
| 16.05.
| Aeterna Zentaris (AEZS) Gets Minimum Bid Notification from Nasdaq | | 9 | StreetInsider.com |
| 16.05.
| Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price | | 8 | CNX Marketlink |
| 16.05.
| Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price | | 41 | PR Newswire |
| QUEBEC CITY, May 16, 2012 /PRNewswire/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that it has
received a notice from The NASDAQ Stock Market indicating...
Mehr lesen zu:
Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price | |
| 09.05.
| Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results | | 75 | PR Newswire |
| All amounts are in U.S. dollars (unless otherwise noted)
QUEBEC CITY, May 9, 2012 /PRNewswire/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today reported financial and
...
Mehr lesen zu:
Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results | |
| 08.05.
| Aeterna, Keryx terminate perifosine license agreement | | 18 | Pharma Bus Review |
| 07.05.
| Aeterna (AEZS), Keryx (KERX) Terminate Perifosine License Agreement in North America | | 10 | StreetInsider.com |
| 07.05.
| Keryx Biopharmaceuticals Announces Reversion of KRX-0401 (Perifosine) License Rights to Aeterna Zentaris | | 44 | PR Newswire |
| NEW YORK, May 7, 2012 /PRNewswire/ --Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the Company and Aeterna Zentaris Inc. have executed a License Termination and Technology Transfer...
Mehr lesen zu:
Keryx Biopharmaceuticals Announces Reversion of KRX-0401 (Perifosine) License Rights to Aeterna Zentaris | |
| 07.05.
| Aeterna Zentaris Regains North American Rights for Perifosine from Keryx | | 29 | PR Newswire |
| Aeterna Zentaris to continue ongoing Phase 3 trial in multiple myeloma
QUEBEC CITY, May 7, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced...
Mehr lesen zu:
Aeterna Zentaris Regains North American Rights for Perifosine from Keryx | |
| 03.05.
| Biotech Industry Will Look to Benefit From New U.S. Patent System / The Paragon Report Provides Stock Research on AEterna Zentaris and Zalicus | | 34 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 05/03/12 -- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date....
Mehr lesen zu:
Biotech Industry Will Look to Benefit From New U.S. Patent System / The Paragon Report Provides Stock Research on AEterna Zentaris and Zalicus | |
| 03.05.
| Aeterna Zentaris to Present at 11th Annual JMP Securities Research Conference in San Francisco | | 22 | PR Newswire |
| QUÉBEC CITY, May 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that its Senior VP and
Chief Medical Officer, Paul Blake MD, will be presenting...
Mehr lesen zu:
Aeterna Zentaris to Present at 11th Annual JMP Securities Research Conference in San Francisco | |
| 01.05.
| Aeterna Zentaris to Announce First Quarter 2012 Financial and Operating Results and Hold Annual Shareholders Meeting on May 9, 2012 | | 42 | PR Newswire |
| QUEBEC CITY, May 1, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") will announce its first quarter 2012
financial and operating results before market open on...
Mehr lesen zu:
Aeterna Zentaris to Announce First Quarter 2012 Financial and Operating Results and Hold Annual Shareholders Meeting on May 9, 2012 | |
| 18.04.
| AEterna Zentaris Looks to Continue to Trade Below its Annual-Low Share Price Today | | 21 | SmarTrend |
| 03.04.
| Recent 52-Week Low Surpassed in Shares of AEterna Zentaris | | 17 | SmarTrend |
| 03.04.
| Downgrade Alert for AEterna Zentaris | | 42 | SmarTrend |
| 03.04.
| Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting | | 53 | PR Newswire |
| AEZS-136 shows synergy and efficacy in human tumor cells
QUÉBEC CITY, April 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX: AEZ) (the "Company") today announced that a poster...
Mehr lesen zu:
Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting | |
| 02.04.
| AEterna Zentaris Down 64.7%, Shares Slide into the Red | | 50 | SmarTrend |
| 02.04.
| XFRA ET8: WIEDERAUFNAHME/RESTART | | 56 | Xetra Newsboard |
| DIE FOLGENDE AKTIE WIRD MIT SOFORTIGER WIRKUNG WIEDER IN DEN HANDEL
AUFGENOMMEN:
THE FOLLOWING SHARE IS RESUMED TRADING WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
AETERNA ZENTARIS...
Mehr lesen zu:
XFRA ET8: WIEDERAUFNAHME/RESTART | |
| 02.04.
| XFRA ET8: AUSSETZUNG/SUSPENSION | | 78 | Xetra Newsboard |
| DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT:
THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
AETERNA ZENTARIS INC. ET8 CA0079752048 BAW...
Mehr lesen zu:
XFRA ET8: AUSSETZUNG/SUSPENSION | |
